Aurinia Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on April 27, 2021, by Aurinia Pharmaceuticals Inc., a company incorporated in Canada. The report discloses corporate governance changes approved by the Board of Directors on April 23, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on amendments to the Company's by-laws and does not contain financial performance data.
Material Changes
The Board approved an amendment to By-law No. 2 to increase the quorum requirement for shareholder meetings. The change was made to align the Company's requirements with those of the Nasdaq Global Market LLC.
- Previous Quorum Requirement: Two shareholders representing at least 25% of issued and outstanding common shares.
- New Quorum Requirement: Two shareholders representing at least 33 1/3% of issued and outstanding common shares.
Outlook, Risks, and Contingencies
The amended by-laws became effective immediately upon Board approval. However, a contingency exists under the Business Corporations Act (Alberta): the amendments will cease to be effective unless they are approved, ratified, and confirmed by a simple majority of votes cast by shareholders at the Company's next annual meeting of shareholders. If not ratified, the pre-existing by-law No. 2 will return to effect.
Key Facts for Investor Verification
- Verify the date and outcome of the next annual meeting of shareholders to confirm if the quorum increase was ratified.
- Confirm the current quorum threshold in effect if the shareholder vote has not yet occurred or if the amendment was rejected.
- Note that this filing contains no financial results or operational updates.